medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2012, Number 2

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2012; 10 (2)

Immunotherapy in malignant melanoma: A review

Díaz MVL, Peniche CA, Fierro AL, Ponce ORM

Language: Spanish
References: 27
Page: 123-138
PDF size: 275.29 Kb.


ABSTRACT

The early and timely surgical treatment is the only method with proven clinical effectiveness in the treatment of malignant melanoma. However, once the malignant melanoma reaches advanced stages, it is highly resistant to conventional therapy and has low response rates and minimal impact on survival. Despite the development of modern techniques of surgery, chemotherapy and radiotherapy, malignant cells often survive and spread, requiring the development of new adjuvant therapies. One of these methods is the manipulation of the immune system to combat tumors, which is called immunotherapy. In recent years several treatments of immunotherapy have been developed in order to treat malignant melanoma and their results are variable. In this article we describe each one of them, characterizing each of the techniques, their advantages and disadvantages.


REFERENCES

  1. Torrella A, Noris-García E. “Inmunoterapia en melanoma”. Oncología 2004; 27(3): 102-107.

  2. López M, Escobar A, Alfaro J, Fodor M, Larrondo M, et al. “Avances en inmunoterapia celular contra el melanoma maligno”. Rev Med Chile 2004; 132: 1115-1126.

  3. Minor DR, Moore AD, Kim AC, Kashani-Sabet AM, Venna BS, et al. “Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy”. The Oncologist 2009; 14: 995-1002.

  4. Riker AI, Radfar S, Liu SH, Wang Y, Khong HT. “Immunotherapy of melanoma: a critical review of current concepts and future strategies”. Expert Opin Biol Ther 2007; 7(3): 345-358.

  5. Noris-García E, Torrella A. “Vacunas en melanoma”. Oncología 2004; 27(3): 108-113.

  6. Kim CJ, Dessureault S, Gabrilovich D, Reintgen DS, Slingluff CL. “Immunotherapy for Melanoma”. Cancer Control 2002; 9(1): 22-30.

  7. Ribas A. Advances in Immunotherapy for the Treatment of Metastatic Melanoma. EU, ASCO’s 2011 Educational Book: 363-366.

  8. Barrio MM. “Melanoma e inmunidad”. Acta Bioquím Clín Latinoam 2009; 43(3): 351-355.

  9. Jakobsen B, Ashfield R, Bossi G, Adams K, Harper J, et al. “Bi-specific TCR anti-CD3 fusion for the immunotherapy of malignant melanoma”. J Immunol 2011; 186: 156-16. (Meeting Abstract Supplement)

  10. Cárdenas ML, García L. “Células dendríticas y melanoma”. Rev Asoc Colomb Dermatol 2010; 18: 218-224.

  11. Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, et al. “Next generation of immunotherapy for melanoma”. J Clin Oncol 2008; 26(20): 3445-3455.

  12. Eggermont AM, Schadendorf D. “Melanoma and immunotherapy“. Hematol Oncol Clin N Am 2009; 23: 547-564.

  13. Polak ME, Borthwick NJ, Gabriel FG, Johnson P, Higgins B, et al. “Mechanisms of local immunosuppression in cutaneous melanoma”. Br J Cancer 2007; 96: 1879-1887.

  14. Wolf IH, Smolle J, Binder B, Cerroni L, Richtig E, et al. “Topical imiquimod in the treatment of metastatic melanoma to skin”. Arch Dermatol 2003; 139: 273-276.

  15. Sigüenza M, Pizarro A, Mayor M, Vidaurrázaga C, Mirelles L, et al. “Tratamiento tópico de las metástasis cutáneas de melanoma con imiquimod”. Actas Dermosifiliogr 2005; 96(2): 111-115.

  16. Spenny ML, Walford J, Werchniak AE, Beltrani V, Brennick JB, et al. “Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports”. Cutis 2007; 79(2): 149-152.

  17. Paterson A, Willans DJ, Jerry LM, Hanson J, McPherson TA. “Adjuvant BCG immunotherapy for malignant melanoma”. Can Med Assoc J 1984; 131: 744-748.

  18. Morton DL, Eilber FR, Holmes EC, Hunt JS, Ketcham AS, Silverstein MJ, et al. “BCG Immunotherapy of malignant melanoma: Summary of a seven-year experience”. Ann Surg 1974; 180(4): 635-641.

  19. Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, et al. “Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome”. J Clin Oncol 2002; 20: 2067–2075.

  20. Mocellin S. “Peptides in melanoma therapy”. Curr Pharm Des 2012; 18(6): 820-831.

  21. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. “Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters”. Cancer Immunol Immunother 2009; 58: 1-14.

  22. Bajetta E, Del Vecchio M, Nova P, Fusi A, Daponte A, et al. “Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma”. Ann Oncol 2006; 17: 571-577.

  23. Atkins MB, Hsu J, Lee S, et al. “Phase III Trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group”. J Clin Oncol 2008; 26(35): 5748-5754.

  24. Mansh M. “Ipilimumab and Cancer Immmunotherapy:A new Hope for Advanced Stage Malanoma”.Yale J Biol Med 2011; 84(4): 381-389.

  25. Pierard GE, Aubin F, Humbert P. “Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma?” Dermatol Res Pract 2012; 2012: 182157.

  26. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, et al. “Improved survival with ipilimumab in patients with metastatic melanoma”. N Engl J Med 2010; 19: 711-723.

  27. Riker AI, Jove R, Daud AI. “Immunotherapy as part of a multidisciplinary approach to melanoma treatment”. Front Biosc 2006; 11: 1-14.




2020     |     www.medigraphic.com